兆科眼科-B(06622)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

06622 兆科眼科-B

未开盘 07-30 15:58:12

2.480

-0.080

-3.12%

最高2.560	最低2.470	成交量26.35万
今开2.560	昨收2.560	日振幅3.52%
总市值13.62亿	流通市值13.62亿	总股本5.49亿
成交额65.44万	换手率0.05%	流通股本5.49亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"06622","market":"HK","secType":"STK","nameCN":"兆科眼科-B","latestPrice":2.48,"timestamp":1785398292788,"preClose":2.56,"halted":0,"volume":263500,"delay":0,"changeRate":-0.03125000000000003,"floatShares":549000000,"shares":549000000,"eps":-0.382096,"marketStatus":"未开盘","change":-0.08,"latestTime":"07-30 15:58:12","open":2.56,"high":2.56,"low":2.47,"amount":654355,"amplitude":0.035156,"askPrice":2.49,"askSize":13500,"bidPrice":2.48,"bidSize":5000,"shortable":0,"etf":0,"ttmEps":-0.4252,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1785461400000},"marketStatusCode":0,"adr":0,"listingDate":1619625600000,"exchange":"SEHK","adjPreClose":2.56,"openAndCloseTimeList":[[1785375000000,1785384000000],[1785387600000,1785398400000]],"volumeRatio":1.1323592610941897,"lotSize":500,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/06622/wiki","defaultTab":"wiki","newsList":[{"id":"2655059788","title":"李氏大药厂(00950.HK)：专有ADC项目ZK2401于中国提交新药临床试验申请获NMPA受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2655059788","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2655059788?lang=zh_cn&edition=full","pubTime":"2026-07-30 22:13","pubTimestamp":1785420782,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1191","00950","BK1574","BK1583","BK1587","06622"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2655846808","title":"一边亏着两个亿，一边押注全球阿托品：兆科眼科的近视神药豪赌","url":"https://stock-news.laohu8.com/highlight/detail?id=2655846808","media":"华夏时报网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2655846808?lang=zh_cn&edition=full","pubTime":"2026-07-30 09:10","pubTimestamp":1785373839,"startTime":"0","endTime":"0","summary":"悬崖边上，落子全球棋局。兆科眼科（6622.HK）近日发布自愿性公告称，公司已于2026年6月22日订立最终协议，收购硫酸阿托品滴眼液NVK002的全球权利。据协议条款，兆科眼科将取得与NVK002相关的全部知识产权、商标、监管档案、临床数据、制造能力及其他相关资产的全球拥有权，全面掌控该产品在全球的开发、制造及商业化工作。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202607303825997988.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202607303825997988.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["BK1191","06622","BK1583","BK1574","BK1587"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1152918833","title":"兆科眼科-B（06622）老花眼创新药YUVEZZI™获澳门药监局批准","url":"https://stock-news.laohu8.com/highlight/detail?id=1152918833","media":"公告速递","labels":["productRelease","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1152918833?lang=zh_cn&edition=full","pubTime":"2026-07-20 12:06","pubTimestamp":1784520369,"startTime":"0","endTime":"0","summary":"兆科眼科-B7月20日公告称，其创新药YUVEZZI已于2026年7月13日获澳门特别行政区政府药物监督管理局批准，用于治疗老花眼。Tenpoint已于2026年1月获得美国食品药品监督管理局批准，将该药用于治疗通常在45岁左右发病的老花眼。同年6月，海南省药品监督管理局亦批准该药作为博鳌超级医院的临床急需进口药品使用。\\n\\n兆科眼科-B提醒股东及潜在投资者，依据香港联合交易所有限公司证券上市规则第18A.05条，公司无法保证最终能成功开发或商业化该药品。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06622"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2652028501","title":"李氏大药厂(00950)就干扰素ALPHA-2B产品与ASHLINS订立大中华地区以外独家许可及供应协议","url":"https://stock-news.laohu8.com/highlight/detail?id=2652028501","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2652028501?lang=zh_cn&edition=full","pubTime":"2026-07-17 21:36","pubTimestamp":1784295413,"startTime":"0","endTime":"0","summary":"智通财经APP讯，李氏大药厂 发布公告，于2026年7月6日，公司与Ashlins Ocular Pharmaceuticals, Inc. 订立独家许可协议。根据该协议，公司同意向Ashlins许可及供应干扰素Alpha-2b，以供其于中国内地、香港、澳门及台湾以外所有地区开发及商业化用于诊断、预防或治疗若干人类疾病的药品。干扰素Alpha-2b乃一种透过重组DNA技术生产的重组人I型干扰素活性药物成分，用作具有抗病毒及免疫调节活性的药品的活性物质。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1469289.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","00950","BK1587","BK1583","BK1191","06622"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651341039","title":"创新药连续大涨，这次真的不一样了吗？","url":"https://stock-news.laohu8.com/highlight/detail?id=2651341039","media":"华尔街见闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651341039?lang=zh_cn&edition=full","pubTime":"2026-07-16 17:05","pubTimestamp":1784192720,"startTime":"0","endTime":"0","summary":"政策上，医保初审通过率创新高，定价机制优化，并建立“医保+商保”双层支付体系；产业上，上半年BD交易总额达1100亿美元，国际竞争力显著提升；资金面上，内外资持续回流。行业正从“讲故事”转向盈利兑现，国金证券认为，2027年有望成为中国创新药海外商业化集中兑现的重要节点。","market":"hk","thumbnail":"https://static.tigerbbs.com/8daedf52c02cecfd417dcbd813afb3fa","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/8daedf52c02cecfd417dcbd813afb3fa"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wallstreetcn.com/articles/3777107","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06618","06606","02268","06622","02137","BK1161","06978","09606","01801","00241","01672","MEDX","09966","BK1574","09995","03347","06996","03759","IBBQ","159992","02269","02359","09688"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2651212817","title":"港股公告掘金 | 佑驾创新与滴滴送货建立长期战略合作关系 拟共同推动城市末端无人配送商业化、规模化落地","url":"https://stock-news.laohu8.com/highlight/detail?id=2651212817","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651212817?lang=zh_cn&edition=full","pubTime":"2026-07-14 08:47","pubTimestamp":1783990072,"startTime":"0","endTime":"0","summary":"重大事项：兆科眼科-B(06622)订立最终协议以收购NVK002(硫酸阿托品滴眼液)的全球权利脑动极光-B(06681)荣获第三届雄安垂直大模型应用大赛亚军及最新临床科研成果在国际权威期刊发表胜宏科技(02476)澄清网络不实负面传闻 AI PCB 订单持续增长佑驾创新(02431)与滴滴送货建立长期战略合作关系 拟共同推动城市末端无人配送商业化、规模化落地恒瑞医药(01276)：HRS-705","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1466963.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU1807302812.USD","BK1184","BK4588","LU0516423174.USD","LU0738912210.USD","LU1242518857.USD","LU0348827113.USD","01109","BK1570","02431","LU0791590937.USD","LU0594300179.USD","HK0000320223.HKD","06622","DIDIY","KCAI","01336","BK1191","LU0516422952.EUR","IE00B3M56506.USD","BK4585","06681","BK1189","LU0211977185.USD","LU2088748293.HKD","BK1144","SG9999009997.SGD","LU0791591158.USD","LU1008478684.HKD","SG9999014674.SGD","BK1555","HK0000306685.HKD","LU0370786039.SGD","LU0516422366.SGD","LU0516423091.SGD","LU0880133367.SGD","LU0359202008.SGD","BK1589","HK0000306701.USD","LU2088748020.USD","LU0173614495.USD","LU0359201612.USD","LU0067412154.USD","HK0000320264.USD","LU0072913022.USD","LU0650527681.SGD","BK1240","LU0048580855.USD","LU0287142896.SGD","VXUS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1137128045","title":"兆科眼科-B敲定最终协议 收购Nvk002全球权益","url":"https://stock-news.laohu8.com/highlight/detail?id=1137128045","media":"美股速递","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1137128045?lang=zh_cn&edition=full","pubTime":"2026-07-13 16:51","pubTimestamp":1783932713,"startTime":"0","endTime":"0","summary":"兆科眼科有限公司已就收购Nvk002的全球权益签署了最终协议。此举标志着该公司在拓展其眼科产品管线方面迈出了关键一步，旨在通过引入新的治疗资产来增强其长期增长潜力。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","BK1587","BK1583","06622","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651929681","title":"兆科眼科-B(06622)订立最终协议以收购NVK002(硫酸阿托品滴眼液)的全球权利","url":"https://stock-news.laohu8.com/highlight/detail?id=2651929681","media":"智通财经","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2651929681?lang=zh_cn&edition=full","pubTime":"2026-07-13 16:49","pubTimestamp":1783932559,"startTime":"0","endTime":"0","summary":"智通财经APP讯，兆科眼科-B 发布公告，于2026年6月22日，公司已收购NVK002的全球权利。NVK002此一产品旨在减慢儿童近视加深。根据协议条款，公司将取得与NVK002相关的所有知识产权、商标、监管存档、临床数据、制造能力及其他相关资产的全球拥有权。本次收购让公司可全面控制该产品在全球的开发、制造及商业化工作。作为交易的一部分，公司已向NVK002的卖方授出一项永久性的免专利权费专属许可，该项权利已出让予Nevakar Pharmaceuticals,Inc.，以于美国开发及商业化NVK002。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1466576.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"兆科眼科-B(06622)订立最终协议以收购NVK002(硫酸阿托品滴眼液)的全球权利","news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06622","BK1587","BK1191","BK1574","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1182810656","title":"兆科眼科授予Nevakar制药公司美国Nvk002永久免版税独家许可","url":"https://stock-news.laohu8.com/highlight/detail?id=1182810656","media":"美股速递","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1182810656?lang=zh_cn&edition=full","pubTime":"2026-07-13 16:48","pubTimestamp":1783932504,"startTime":"0","endTime":"0","summary":"兆科眼科已授予Nevakar制药公司一项关于Nvk002的永久、免版税、在美国的独家许可。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06622","BK1587","BK1574","BK1191","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1160013342","title":"兆科眼科-B：7月9日回购8,500股，耗资约2.21万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1160013342","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1160013342?lang=zh_cn&edition=full","pubTime":"2026-07-09 17:32","pubTimestamp":1783589572,"startTime":"0","endTime":"0","summary":"兆科眼科有限公司于2026年7月9日公告，于香港联合交易所场内回购公司股份8,500股，占已发行股本约0.0015%，回购价格介乎每股港币2.58元至2.62元，合计支付约2.21万港元。根据翌日披露报表，本次回购后公司已发行股本仍为548,749,012股，暂未产生库藏股变动。公司于2026年5月15日通过购回授权，可购回最多54,874,901股。公司确认本次回购已获得董事会正式授权，遵守了香港联合交易所证券上市规则及相关法律规定。公告由董事李小羿签署。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"兆科眼科-B：7月9日回购8,500股，耗资约2.21万港元","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06622"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2650492886","title":"兆科眼科-B(06622)7月9日斥资2.21万港元回购8500股","url":"https://stock-news.laohu8.com/highlight/detail?id=2650492886","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2650492886?lang=zh_cn&edition=full","pubTime":"2026-07-09 17:32","pubTimestamp":1783589552,"startTime":"0","endTime":"0","summary":"智通财经APP讯，兆科眼科-B(06622)发布公告，于2026年7月9日斥资2.21万港元回购8500股。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1465355.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06622","BK1583","BK1574","BK1191","BK1587"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1116537093","title":"兆科眼科-B - Yuvezzitm 获准在博鳌超级医院作为临床急需进口药物使用","url":"https://stock-news.laohu8.com/highlight/detail?id=1116537093","media":"美股速递","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1116537093?lang=zh_cn&edition=full","pubTime":"2026-07-07 12:06","pubTimestamp":1783397211,"startTime":"0","endTime":"0","summary":"兆科眼科-B 宣布，其药物 Yuvezzitm 已获准在海南博鳌超级医院作为临床急需进口药物投入临床使用。此举标志着该产品在满足特定临床需求方面取得了重要进展。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06622","BK1583","BK1191","BK1587","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1177330865","title":"兆科眼科-B7月6日回购11,000股，耗资约2.91万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1177330865","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1177330865?lang=zh_cn&edition=full","pubTime":"2026-07-07 08:04","pubTimestamp":1783382665,"startTime":"0","endTime":"0","summary":"兆科眼科-B于2026年7月6日发布翌日披露公告，披露当日通过香港联交所场内回购普通股11,000股，每股回购价介乎港币2.638元至2.65元，合计付出价格29,104.90港元。该回购股份数量约占公司现有已发行股本的0.002%。根据2026年5月15日通过的股份回购授权，兆科眼科-B可回购最多54,874,901股。公司同时确认，回购过程符合香港联交所证券上市规则及相关法律法规的要求。上述公告由公司董事李小羿签署。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"兆科眼科-B7月6日回购11,000股，耗资约2.91万港元","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06622"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649867738","title":"兆科眼科-B(06622.HK)7月6日斥资2.91万港元回购1.1万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2649867738","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2649867738?lang=zh_cn&edition=full","pubTime":"2026-07-07 08:02","pubTimestamp":1783382571,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1583","BK1191","BK1574","06622","BK1587"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1141514578","title":"兆科眼科-B7月3日回购7,500股股份，总额约1.96万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1141514578","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1141514578?lang=zh_cn&edition=full","pubTime":"2026-07-03 17:49","pubTimestamp":1783072185,"startTime":"0","endTime":"0","summary":"兆科眼科-B于2026年7月3日发布公告，公司当日在香港联交所场内回购普通股7,500股，占该公司当日已发行股本约0.0014%。本次回购价格区间介乎每股2.58港元至2.615港元，共计支付19,610.25港元。回购完成后，公司已发行股本保持548,749,012股，库存股仍为0股。本次回购根据2026年5月15日通过的购回授权进行，授权数量为54,874,901股。公告显示，截至本次回购，兆科眼科-B已合计回购1,700,000股，占获授权当日公司已发行股本的约3.098%，剩余可回购股份为53,174,901股。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"兆科眼科-B7月3日回购7,500股股份，总额约1.96万港元","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06622"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1101047229","title":"兆科眼科-B更新2026年6月股份变动月报表，股本维持548,749,012股","url":"https://stock-news.laohu8.com/highlight/detail?id=1101047229","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1101047229?lang=zh_cn&edition=full","pubTime":"2026-07-03 12:09","pubTimestamp":1783051750,"startTime":"0","endTime":"0","summary":"兆科眼科有限公司于2026年7月3日披露截至2026年6月30日止的证券变动月报。公告显示，公司法定股本为1,600,000,000,000股，每股面值0.00000025美元，注册股本合计400,000美元。报告期内，兆科眼科-B已发行股份数为548,749,012股，与上月末持平，暂无新增发行或储备股份转让。公司在公告中确认，其所有证券发行及回购股份事宜均符合法律法规及香港联交所《上市规则》的相关规定，并已履行相应的审批程序。本公告由公司董事李小羿代表董事会签署。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06622"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648163441","title":"兆科眼科-B(06622.HK)7月2日斥资10.21万港元回购3.95万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2648163441","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2648163441?lang=zh_cn&edition=full","pubTime":"2026-07-03 09:02","pubTimestamp":1783040571,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["06622","BK1583","BK1587","BK1574","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1179988057","title":"兆科眼科-B：7月2日回购39,500股股份，涉资约10.21万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1179988057","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1179988057?lang=zh_cn&edition=full","pubTime":"2026-07-03 09:02","pubTimestamp":1783040528,"startTime":"0","endTime":"0","summary":"兆科眼科有限公司于2026年7月2日公告，进行了股份回购交易。该公司当日在香港联交所场内回购39,500股普通股，占已发行股本的约0.0072%。回购价格介乎每股2.57港元至2.5849港元，总金额约10.21万港元。截至2026年7月2日，兆科眼科-B已发行股本合计为548,749,012股且无库存股份。根据公告，购回授权于2026年5月15日获股东大会通过，公司最多可回购54,874,901股，迄今已合计回购1,692,500股，相当于授权通过当日公司已发行股份总数的约3.0843%。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"兆科眼科-B：7月2日回购39,500股股份，涉资约10.21万港元","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06622"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1140088829","title":"兆科眼科-B：6月30日回购9.20万股，涉资约22.94万港元","url":"https://stock-news.laohu8.com/highlight/detail?id=1140088829","media":"公告速递","labels":["shareholding","SGX"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1140088829?lang=zh_cn&edition=full","pubTime":"2026-06-30 17:14","pubTimestamp":1782810864,"startTime":"0","endTime":"0","summary":"2026年6月30日，兆科眼科-B（06622）在香港联交所公告，称公司于当日通过场内交易回购普通股合计9.20万股，每股回购价格介乎2.4806港元至2.5034港元，合计耗资约22.94万港元。\n公告显示，自2026年5月15日购回授权获批以来，截至6月30日，兆科眼科-B已在香港联交所及其他证券交易所累计回购普通股1,653,000股，占购回授权通过当日公司已发行股份总数的3.0123%。截至上述日期，公司已发行股本维持在548,749,012股，库藏股数为0，所购回股份尚未办理注销手续。\n公司董事会确认，本次购回事项均获正式授权并遵守上市规则及相关法律法规。公告由董事李小羿签署。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"兆科眼科-B：6月30日回购9.20万股，涉资约22.94万港元","news_tag":"shareholding,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06622"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2647539907","title":"兆科眼科-B(06622)6月30日斥资约22.94万港元回购9.2万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2647539907","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2647539907?lang=zh_cn&edition=full","pubTime":"2026-06-30 17:11","pubTimestamp":1782810682,"startTime":"0","endTime":"0","summary":"智通财经APP讯，兆科眼科-B(06622)发布公告，于2026年6月30日该公司斥资约22.94万港元回购9.2万股，回购价格为每股2.4806至2.5034港元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1461166.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1587","BK1191","BK1574","BK1583","06622"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"stockEarnings":[{"period":"1week","weight":-0.057},{"period":"1month","weight":-0.012},{"period":"3month","weight":-0.1448},{"period":"6month","weight":-0.3261},{"period":"1year","weight":-0.2026},{"period":"ytd","weight":-0.1622}],"compareEarnings":[{"period":"1week","weight":0.0257},{"period":"1month","weight":0.1301},{"period":"3month","weight":0.0032},{"period":"6month","weight":-0.0558},{"period":"1year","weight":0.0271},{"period":"ytd","weight":0.0089}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"兆科眼科有限公司是一家主要从事眼科药物及产品的开发、生产及营销的投资控股公司。该公司的主要产品包括用于治疗近视的NVK002（阿托品）、用于治疗干眼症的环孢素A眼凝胶以及用于治疗wAMD的TAB014（贝伐单抗）。该公司产品主要用于干眼症（DED）、近视、老花眼、湿性老年黄斑部病变（wAMD）和糖尿病黄斑水肿（DME）、青光眼及角膜上皮细胞功能障碍（CED）等影响眼前节及眼后节的眼科疾病的治疗。该公司在中国国内及海外市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.6,"avgChangeRate":0.147188},{"month":2,"riseRate":0.2,"avgChangeRate":-0.134185},{"month":3,"riseRate":0.2,"avgChangeRate":-0.040318},{"month":4,"riseRate":0.2,"avgChangeRate":0.019445},{"month":5,"riseRate":0.333333,"avgChangeRate":0.015956},{"month":6,"riseRate":0.166667,"avgChangeRate":0.033584},{"month":7,"riseRate":0.333333,"avgChangeRate":-0.047805},{"month":8,"riseRate":0.2,"avgChangeRate":-0.017626},{"month":9,"riseRate":0.6,"avgChangeRate":0.007418},{"month":10,"riseRate":0.2,"avgChangeRate":-0.082811},{"month":11,"riseRate":0.4,"avgChangeRate":0.029799},{"month":12,"riseRate":0.2,"avgChangeRate":-0.018114}],"exchange":"SEHK","name":"兆科眼科-B","nameEN":"ZHAOKE OPHTH-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"兆科眼科-B(06622)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供兆科眼科-B(06622)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"兆科眼科-B,06622,兆科眼科-B股票,兆科眼科-B股票老虎,兆科眼科-B股票老虎国际,兆科眼科-B行情,兆科眼科-B股票行情,兆科眼科-B股价,兆科眼科-B股市,兆科眼科-B股票价格,兆科眼科-B股票交易,兆科眼科-B股票购买,兆科眼科-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"兆科眼科-B(06622)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供兆科眼科-B(06622)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}